Media & Resources

Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access.

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV.

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

IAVI to apply expertise in viral vector vaccines to Lassa Fever prevention effort.

Adel A. F. Mahmoud, MD, PhD, was a member of the IAVI Board of Directors from 2012. He was an important advocate for a global focus on vaccine development and equitable access, including the importance of advancing HIV R&D.

The Coalition for Epidemic Preparedness Innovations (CEPI) and IAVI announce partnership to develop a Lassa fever vaccine.

IAVI will receive a total of DKK 20 million (USD $3.18 million) from 2018-2021, administered by the Danish Ministry of Foreign Affairs.

Linda-Gail Bekker, Mark Dybul, and Christina Hull Paxson join IAVI Board in 1Q 2018.